Uriach Increases Revenue by 16% in 2022, by Over €272 Million

Uriach continues to increase its income. The Catalan pharmaceutical laboratory has closed the 2022 financial year with a turnover of more than €272 million, which translates into an increase of 15.7% compared to 2021, as explained by Oriol Segarra, CEO of Uriach, this morning in Barcelona in statements to the media. The company also aims its international growth at France, a country in which it hopes to close a corporate operation.

Uriach grows at double digits for the tenth consecutive year and confirms its strategic shift to focus 100% on the natural consumer healthcare (Nchc) business. A market niche that Uriach aspires to lead in Europe in the coming years, already being one of its main players on the continent. 

Beyond the growth in turnover, profitability follows the same positive trend, with a gross operating result (Ebitda) that exceeded €40 million in 2022, 5.2% more than the previous year. Looking ahead to 2023, the group expects to achieve a turnover of approximately €310 million and an Ebitda of €45 million, that is, above 15%.

Read more about Uriach and find the most important business news of the day with our companion app Born2Invest.

Uriach plans to reach a turnover of €310 million in 2023

In Segarra’s words, “These are great results, taking into account the difficulties of the situation experienced in 2022 due to inflation, the scarcity of some raw materials, supply difficulties, the impact of the war in Ukraine, and the increase in interest rates.”

Referring to the strategy of inorganic growth and geographical expansion, in 2022, Uriach acquired the Romanian company Medimow, dedicated to the development and marketing of food supplements for pain, gynecology, and pediatrics, among other specialties, and distributor of its Uriach products since 2018.

In October 2022, Uriach also completed the acquisition of the HuPaVir brand, a supplement to combat human papillomavirus (HPV) infections and lesions.

Likewise, the company continues to bet on its plan for 2025 and expects to reach a turnover of between 450 million euros and 500 million euros. To achieve these figures, the company expects to be able to close some more acquisitions in the next two years.

In the last eight years, Uriach has managed to have a direct presence in seven European countries: Spain; Italy (purchasing Laborest in 2015, and in 2019 ARFitofarma and Progine); Portugal (Theralab acquisition in 2018); Germany, Austria, and Switzerland (through the purchase of Sidroga in 2021); and Romania, after the acquisition of Medimow in 2022. In addition, it maintains a joint venture agreement for the commercialization of its brands (Aquilea, Fisiocrem, or Laborest) in Greece.

__

(Featured image by kkolosov via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.